FROM THE EDITOR
Every CLO who has been in the room when the FDA Complete Response Letter arrives knows what the next 72 hours feel like. The science team is devastated. The commercial team is trying to calculate what the miss means for the quarter. The CEO is on the phone with the board chair. And the legal team is the only function in the building that cannot be devastated, cannot panic, and cannot lose sight of the specific, sequential obligations that the next three days require.
I have been in that room. The CRL itself is a document. What matters is what happens in the 72 hours after it arrives. Who gets told, in what order, and when. What the company says publicly, and whether that statement will survive comparison with what FDA writes. How fast the plaintiff’s bar moves, and whether the litigation hold is already in place when they do. Whether the board understands what the letter actually says before it reads about it in the press.
In July 2025, FDA changed the calculus entirely. The Agency announced a ‘radical transparency’ initiative and began publishing Complete Response Letters in near real time. More than 200 previously undisclosed CRLs were released at once. Eighty-nine more followed in September 2025. FDA announced that going forward, CRLs would be published promptly after issuance. The company’s prior disclosures about its development program — every risk factor in every 10-K, every comment on every earnings call — are now compared in real time against the published letter. The three days of uncertainty have compressed. The window to shape the narrative before FDA publishes its version has narrowed to hours.
This article is the protocol. Three days. What the CLO owns in each one.
— John LaRocca
Founding Editor | LaRocca Advisory Group
Three Days of Uncertainty: The CLO’s Complete Response Letter Protocol Under FDA’s Radical Transparency Regime
Covers: FDA CRL disclosure, 8-K materiality, Reg FD, securities litigation preparedness, FDA’s real-time publication regime, crisis communication protocol
The Changed Landscape: What FDA’s Radical Transparency Did to the CLO’s Window
For the first 25 years of my career, the Complete Response Letter was a private document. FDA issued it to the applicant. The applicant decided when and how to disclose it to the public. That decision involved genuine discretion: a small company whose entire pipeline rested on a single NDA disclosed immediately because the market would find out anyway. A large company with 40 marketed products might disclose on the next quarterly report if the program was not individually material. The CLO had a window — sometimes 24 hours, sometimes 48, sometimes a week — to assess materiality, draft the 8-K, brief the board, and prepare the investor communication before the public knew.
That window is gone.
In July 2025, FDA announced it would publish CRLs in near real time, stating that sponsors had historically misrepresented the rationale behind FDA’s decisions to their stakeholders. FDA released more than 200 previously unpublished letters at once and committed to publishing new ones promptly after issuance. By April 2026, firms were advising pharmaceutical clients that redacted CRLs would be released shortly after issuance, enabling stakeholders to assess company disclosures against FDA’s contemporaneous written communication — and that discrepancies between company statements and FDA’s published rationale would be cited in securities complaints or enforcement actions.
The practical consequence for the CLO: the company may receive the CRL at 8 AM and find it on FDA’s website by early afternoon. Every statement the company has made about this program — in the 10-K, in the most recent earnings call, in the investor deck presented at the JPMorgan Healthcare Conference — is now evidence against which the FDA letter will be compared. The assessment and drafting work that used to take 48 hours must now be substantially complete before FDA publishes, not after.
The three days of uncertainty have not shortened. The work inside them has intensified.
WHAT A CRL ACTUALLY IS — AND WHY IT MATTERS FOR DISCLOSURE
A Complete Response Letter is FDA’s formal notification that an NDA or BLA cannot be approved in its current form. It identifies specific deficiencies and provides the applicant with three options: resubmit the application (Class 1 with a 2-month PDUFA review goal, or Class 2 with a 6-month review goal), withdraw the application, or request a hearing. CRLs are not rejection letters — many drugs that receive CRLs eventually achieve FDA approval. But the short-term market impact of a CRL on a small or mid-cap biotech can be existential. The company that receives a CRL for its lead asset on a Monday and handles disclosure and investor communication poorly is a different company by Thursday.
The Three Days: What the CLO Owns
The three-day framework is not a metaphor. It is a sequenced protocol. The specific actions, their order, and who owns them determine whether the company manages the CRL or the CRL manages the company.
DAY 1 The Assessment Window
WINDOW: CRL receipt to FDA’s publication (hours, not days under the current regime)
THE CLO OWNS: The legal team owns: (1) reading the letter completely, (2) determining materiality, (3) identifying every prior public statement that the letter’s findings touch, (4) convening the crisis team, (5) beginning the 8-K draft
SPECIFIC TASKS: Read the full letter before doing anything else. Not the executive summary. The letter itself. FDA’s stated rationale is the document your disclosure will be compared against. Identify: the specific deficiencies cited; the CMC, clinical, or labeling category each falls into; the resubmission pathway FDA has indicated; and any language in the letter that contradicts, qualifies, or contextualizes statements the company has made in public filings. Call outside securities counsel immediately. Call regulatory counsel if not already in the room. Convene the executive team: CEO, CFO, CMO, Chief Commercial Officer, and IR. Do not talk to investors, analysts, or journalists before the 8-K is filed. Reg FD applies from the moment the CRL is received.
DAY 2 The Disclosure Day
WINDOW: 8-K filing through the end of the investor call
THE CLO OWNS: The legal team owns: (1) 8-K accuracy reviewed against FDA’s letter language, (2) press release language approved by securities and regulatory counsel jointly, (3) investor call script reviewed for Reg FD compliance, (4) board briefed before disclosure, (5) IR messaging aligned with disclosure
SPECIFIC TASKS: The 8-K must be filed before the markets open if the CRL was received before market hours, or on a current report basis if received during trading. The materiality threshold for a CRL is context-dependent — for a small biotech whose lead asset is at issue, it is almost always material. For a large pharma company, the analysis requires a quantitative assessment of what the delayed or failed approval means for revenue, guidance, and pipeline. Whatever the conclusion, document the materiality analysis. The press release language must be reviewed against the CRL’s actual text, sentence by sentence. Every characterization of FDA’s concerns must match what FDA actually wrote. Under FDA’s real-time publication regime, analysts and plaintiff’s counsel will have the letter within hours. Any divergence between the company’s characterization and FDA’s text is evidence of misleading disclosure. The investor call script requires Reg FD review: no material non-public information disclosed orally that was not in the 8-K, no optimistic language that outpaces what the 8-K actually says.
DAY 3 The Litigation Window
WINDOW: 48-72 hours after the 8-K — the securities class action arrives
THE CLO OWNS: The legal team owns: (1) litigation hold, (2) document preservation, (3) outside litigation counsel retained, (4) D&O insurance carrier notified, (5) internal communications protocol established
SPECIFIC TASKS: Securities class action attorneys monitor FDA databases and 8-K filings. For a company whose stock falls 30% or more on CRL disclosure, the complaint is filed within 48-72 hours. The litigation hold must be in place before the complaint arrives, not after. The hold covers: all communications about the FDA submission and clinical program dating back to the IND; all internal communications about the PDUFA date and the company’s own assessment of approval probability; all communications between the clinical and regulatory teams about any issues identified in the NDA prior to submission; and any communications with investment banks, analysts, or investors about the program’s prospects. Do not allow employees to delete, archive, or reorganize files related to the program once the CRL is received. Outside litigation counsel needs to be on the phone on Day 1, not Day 3. D&O carriers must be notified immediately — most D&O policies require prompt notification of circumstances that may give rise to a claim.
The Documents That Survive Scrutiny and Those That Do Not
The disclosure that survives securities litigation under FDA’s real-time CRL publication regime has four characteristics. Getting all four right is harder than it sounds.
It matches what FDA actually wrote
Every characterization of FDA’s concern must be consistent with the language in the published CRL. FDA wrote that the clinical data did not demonstrate a statistically significant treatment effect in the primary endpoint. The company’s press release says FDA expressed concerns about the study’s statistical methodology. Those statements are not the same. The plaintiff’s expert will say so in the complaint, and they will be right. Review the 8-K and press release against the CRL line by line before filing.
It does not overstate the company’s path forward
A CRL is a solvable problem for many products. Class 1 resubmission timelines are two months. Resubmissions succeed. But the press release that says ‘we are confident in our ability to address FDA’s concerns and expect to resubmit within six months’ — written within hours of receiving a CRL citing multiple clinical deficiencies — will be cited in the securities complaint as an example of management’s misleading optimism. The path forward language must be calibrated to what you actually know at the time of disclosure. If you have not yet had time to assess the full scope of the remediation required, say that. ‘We are reviewing the letter and will provide additional information on our response timeline after that review is complete’ is a legally safer statement than a specific timeline that you have not yet validated.
It aligns with what the company has said before
Every prior public statement about the NDA or BLA is now evidence. The risk factor that said ‘FDA may not approve our lead product’ is fine. The earnings call comment that said ‘we have high confidence in our NDA package and expect approval’ is a problem if the CRL identifies deficiencies that were known to the regulatory team before submission. The CLO needs to pull the full disclosure record — every 10-K risk factor, every earnings call comment, every investor presentation, every offering document — and compare it against the CRL’s stated deficiencies. Any gap between what was said and what FDA found is a potential securities fraud allegation.
It was reviewed by both regulatory and securities counsel simultaneously
This is the organizational failure that produces the most preventable securities cases. The press release is drafted by investor relations, reviewed by regulatory affairs, and approved by the CEO. Securities counsel is not in the room. The company’s characterization of FDA’s concern is accurate in regulatory terms but misleading in securities disclosure terms. Under FDA’s real-time publication regime, the standard of joint review — both regulatory and securities counsel reviewing every public statement about a CRL simultaneously — is not a best practice. It is a minimum.
Before the Letter Arrives: Building the Protocol Now
The CLO who reads this article and implements a CRL response protocol before receiving a CRL is the CLO who manages the three days. The CLO who builds the protocol in real-time during the crisis is playing catch-up from the moment the letter arrives.
Every pharma and biotech company with an active NDA, BLA, or late-stage IND should have a written CRL response protocol in place that answers ten specific questions before the letter ever arrives:
• Who receives the CRL first, and who is notified in what order in the first 30 minutes?
• Who is on the crisis team, and who has the authority to convene it on 20 minutes notice?
• Which outside securities counsel is on retainer and can be reached immediately?
• Which outside litigation counsel will handle the securities class action that arrives 48 hours after disclosure?
• What is the materiality analysis framework for this specific program relative to this company’s overall portfolio?
• Where is the full disclosure record — every public statement about this program — assembled and retrievable?
• What is the document preservation hold protocol, and who executes it the moment a CRL is received?
• Who notifies the D&O carrier, and what does the policy require in terms of timing?
• What is the board notification protocol — does the board chair get a call before the 8-K is filed?
• Who reviews the press release and investor call script against the CRL text before either is published?
Companies that answer these ten questions in writing, before the CRL arrives, manage the three days. Those that answer them in real-time, under pressure, while the FDA is publishing the letter they just received, manage outcomes that could have been prevented. What follows are the workstreams I would encourage CLO’s to undertake to best address this issue.
WORKSTREAM 1 IMMEDIATE
Build and Test the CRL Response Protocol Before the Next PDUFA Date
For every product with an active PDUFA date in the next 18 months: build the written CRL response protocol, assign owners to each of the ten questions above, and conduct a tabletop exercise with the crisis team before the PDUFA date. The tabletop should simulate the scenario where the CRL arrives at 8 AM and FDA publishes a redacted version by noon. Walk through every decision: who is called first, who drafts the 8-K, who reviews it against the CRL text, who approves the press release, what the investor call script says and does not say, and how the litigation hold is executed. If the exercise surfaces gaps — outside securities counsel without a current engagement letter, D&O carrier notification procedures that require more than one business day, a disclosure record that has never been assembled in one place — close those gaps before the PDUFA date, not after it.
BUSINESS IMPACT: A tabletop exercise that surfaces a gap in the protocol costs a few hours. A securities class action that exploits that gap costs years and tens of millions of dollars. These are not comparable risks.
WORKSTREAM 2 NEAR-TERM
Conduct a Full Disclosure Record Review for Every Active Late-Stage Program
For every product with an active NDA, BLA, or Phase 3 program that is approaching the IND-to-NDA transition: pull the complete disclosure record and compare it against the program’s internal regulatory assessment of approval risk. The disclosure record includes every 10-K risk factor about this program, every earnings call comment, every investor presentation, every offering document, and every press release that mentioned the program’s status or prospects. The internal regulatory assessment includes every Type B and Type C meeting summary with FDA, every formal dispute resolution submission, and any internal communication that assessed the probability of a CRL. Under FDA’s real-time publication regime, the gap between what the company said publicly and what FDA actually found is the space where securities fraud claims are born. Identify the gaps now, when there is still time to update disclosures in the ordinary course.
BUSINESS IMPACT: A disclosure record review conducted before the CRL arrives gives the company time to update risk factors and calibrate forward-looking statements. A disclosure record review conducted after the CRL arrives is document preservation for litigation.
WORKSTREAM 3 NEAR-TERM
Establish the Joint FDA-Securities Review Protocol for All Program-Related Public Statements
Under FDA’s real-time CRL publication regime, every public statement about an active regulatory program sits at the intersection of FDA regulatory law and securities disclosure law. Both regulatory counsel and securities counsel must review every earnings call comment, investor presentation, and press release about active regulatory programs — not sequentially but simultaneously. The process change is specific: add securities counsel to the review distribution for all investor-facing communications about regulatory programs that have live PDUFA dates or pending submissions. Regulatory counsel ensures the statement is accurate in FDA terms. Securities counsel ensures the statement is complete in securities disclosure terms. The two are not the same standard. An accurate regulatory description can be a misleading securities disclosure if it omits material information. Build the joint review into the IR communications calendar — not as an ad hoc escalation, but as a standing process for every communication about an active regulatory program.
BUSINESS IMPACT: A press release about a Phase 3 readout reviewed by regulatory but not securities counsel is a disclosure that has been reviewed for one of the two standards it will be judged against. Under FDA’s current transparency regime, that gap is no longer a remote risk.
“The three days after a CRL arrives are the three days that define whether the legal team was ready or reactive. The CLO who builds the protocol before the PDUFA date is the one who manages the crisis. The CLO who builds it during the crisis manages the damage.”
laroccaj.substack.com | Subscribe: $40/month or $400/year
ABOUT THE AUTHOR
John LaRocca is a pharma and biotech attorney with 26 years of in-house experience, including CLO/GC tenures at Actavis, Eagle Pharmaceuticals, Aerie Pharmaceuticals, and Y-mAbs Therapeutics. He is the founding partner of LaRocca Advisory Group, a boutique fractional CLO services firm. The GC Playbook reflects his personal views and does not constitute legal advice.
© 2026 The GC Playbook | All rights reserved | Not for redistribution without permission


